Skip to main content
All lobbying filings

CARDINAL HEALTH, INC.

CARDINAL HEALTH, INC. filed a Q3 report for CARDINAL HEALTH INC on October 17, 2025.

Lobbying for CARDINAL HEALTH INC

All filings by CARDINAL HEALTH, INC. · Everything CARDINAL HEALTH INC has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 17, 2025
Expenses
$390,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Ohio

Official filing document

 Government bodies contacted 9

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 4
Health Issues

Issues related to drug pricing, bona fide service fees, Affordable Care Act subsidies, pharmacies, provider status, biosimilars, cell and gene therapy, food is medicine and issues related to provider reimbursement, Medicare and Medicaid, workforce shortages, and product shortages (H.R.4299 Protecting Patient Access to Cancer and Complex Therapies Act; H.R.5031 Preserving Patient Access to Long-Term Care Pharmacies Act; H.R.3164/S.2426 Ensuring Community Access to Pharmacist Services Act). Issues related to DMEPOS supplies, competitive bidding, reimbursement to home health agencies, and acute hospital care at home services (H.R.5142 Home Health Stabilization Act of 2025).

Manufacturing

Education on supply chain issues, drug shortages, domestic manufacturing, medical device environmental issues; Issues related to the medical supply chain and transportation.

Trade (domestic/foreign)

Issues related to tariffs, trade, and U.S. trade policy.

Tariff (miscellaneous tariff bills)

Issues related to tariffs, trade, and U.S. trade policy.

 Bills named in this filing 5
  • H.R. 4299
    Protecting Patient Access to Cancer and Complex Therapies Act
  • H.R. 5031
    Preserving Patient Access to Long-Term Care Pharmacies Act
  • H.R. 3164
    Ensuring Community Access to Pharmacist Services Act
  • S. 2426
    Equitable Community Access to Pharmacist Services Act
  • H.R. 5142
    Home Health Stabilization Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem